Table 4

Factors at baseline associated with day 45 evaluation after excluding possible IA

VariableaData [no., no. (%), or median (range)] for indicated patient(s)Pb
Responder (n = 22)Nonresponder (n = 24)Undetermined (n = 2)
Age (yr)52.1 (15.6–77.8)45.0 (9.8–71.9)31.5 and 63.90.27
Patient risk category0.64
    Allogeneic HSCT9 (41)13 (54)0 (0)
    AL8 (36)6 (25)1 (50)
    Others5 (23)5 (21)1 (50)
EORTC-defined IA1.00
    Proven2 (9)2 (8)0 (0)
    Probable20 (91)22 (92)2 (100)
Leukocyte count <100/mm3 at diagnosis9 (41)11 (46)0 (0)0.77
Receiving corticosteroids10 (45)18 (75)2 (100)0.069
Cumulative dose of prednisone (mg/kg of body wt) the week before diagnosis0.0 (0.0–11.0)7.0 (0.0–28.0)7.0 and 31.00.018
Received immunosuppressive therapy for <1 month7 (32)12 (50)0 (0)0.24
Received antimold therapy for <15 days11 (50)18 (75)0 (0)0.13
Concomitant pulmonary infection8 (36)8 (33)0 (0)1.00
Serum GM antigen value0.8 (0.1–9.3)1.3 (0.1–11.0)0.2 and 4.80.064
    Patients with value of ≥0.514 (64)15 (62)1 (50)1
BAL fluid GM antigen value3.4 (0.1–9.8)0.8 (0.0–7.0)0.027
    Patients with value of ≥0.510 (83)8 (57)0.22
Anti-Aspergillus antibody value3.3 (1.0–181.0)3.4 (1.0–108.0)0.2 and 8.10.9
    Patients with value of ≥124 (19)6 (25)0 (0)0.73
Positive mycological examination of respiratory samples13 (76)14 (70)1 (100)0.72
Positive PCR for Aspergillus fumigatus1 (6)3 (21)0 (0)0.32
Positive PCR for Aspergillus spp.8 (50)3 (23)1 (100)0.25
First-line treatment with voriconazole12 (82)20 (83)1 (50)1.00
Halo sign12 (55)13 (54)0 (0)1.00
  • a HSCT, hematopoietic stem cell transplantation; GVHD, graft versus host disease; AL, acute leukemia; CS, corticosteroids; GM, galactomannan.

  • b Fisher's exact test or Wilcoxon rank-sum test for responders versus nonresponders.